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Abstract: Our laboratory has been investigating the impact of a neurotoxic exposure to methamphetamine (METH) on 
cellular components of the striatum post-synaptic to the dopaminergic terminals. A systemic bolus injection of METH (30 
mg/kg, ip) induces the production of new cells in the striatum during a period lasting from 24-48 hours after METH. The 
newly generated cells arise from dormant striatal progenitors and not from the subventricular zone. The newly generated 
cells display glial phenotypes and begin to die 24 hours after birth, or 2.5 days post-METH. The protracted phase of cell 
death lasts for at least three months post-METH at which time the bulk of the newly generated cells have disappeared. The 
METH-induced production of new cells is associated with enlarged striatal volume (up to 50% larger than controls   
in some animals). As the newly generated cells die over a period of three months, the enlarged striatal volume normalizes. 
In conclusion, a neurotoxic dose of METH induces the generation of new cells in the striatum associated with enlarged 
striatal volume. The new cells die over three months post-METH and the enlarged striatal volume returns to control levels. 
This observation is significant because studies involving METH users show striatal enlargement and the normalization of 
striatal volume in METH users who have been abstinent for up to 20 months. 
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INTRODUCTION 
  Methamphetamine (METH) is an illicit drug that has 
been increasing in popularity for recreational use and   
according to recent estimates has become the second most 
abused drug after marijuana [1]. The illicit use of METH is a 
great burden on society because METH use is associated 
with aggressive behavior that is a major problem for law 
enforcement [2, 3]. Recent studies demonstrate that acute 
and chronic METH use induces neurotoxic responses in the 
human brain that can further deteriorate into neural damage 
including structural abnormalities. For example, studies util-
izing positron emission tomography showed decreased levels 
of dopamine transporter [4, 5] and serotonin transporter sites 
[6] in various brain regions including the caudate and pu-
tamen. Detoxified METH users showed increased glucose 
metabolism (an index of brain function) in parietal brain 
regions but decreased glucose utilization in the striatum and 
thalamus [7]. Magnetic resonance imaging studies demon-
strated that the brains of METH users display significant 
deficits in gray-matter in the cingulated, limbic and paralim-
bic cortices suggesting the loss of neurons [8]. A separate 
study demonstrated the enlargement of the caudate nucleus, 
globus pallidus and putamen, nucleus accumbens and the 
parietal cortex of adult METH users [9, 10]. 
  The mechanism of action of METH has been studied 
extensively in animal model species such as the rodent. In 
the rodent brain, METH induces long-term depletion of do-
pamine transporters and tyrosine hydroxylase in striatal   
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dopaminergic terminals [11, 12], depletion of tryptophan hy- 
droxylase in serotonergic terminals [13], and degeneration of 
neural tissue in the striatum [14]. In addition to deficits in 
pre-synaptic dopaminergic terminals of the striatum, METH 
induces the loss of neurons in various brain regions such as 
the cortex and striatum [15-17]. In the present study, we 
have investigated the METH-induced loss of striatal neurons 
over a period of three months. METH induces rapid cell loss 
(24 hours) followed by the generation of new cells that die 
over a period of three months. The increased number of new 
cells is associated with enlargement of the striatum that nor-
malizes over a period of three months post-METH. 
MATERIALS AND METHODS 
Animals 
  Male ICR mice (Taconic, Germantown, NY) between 10 
to 13 weeks of age were housed individually on a 12-h 
light/dark cycle with food and water available ad libitum. 
The mice were habituated for two weeks prior to com-
mencement of intraperitoneal (i.p.) drug administration. All 
procedures regarding animal use were performed in accor-
dance with the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals and were approved by 
the Institutional Animal Care and Use Committee at Hunter 
College of the City University of New York. 
Drug Preparation and Treatment 
  (+)-Methamphetamine hydrochloride (Sigma, St. Louis, 
MO) was dissolved in 10 mM phosphate-buffered saline, pH 
7.4 (PBS) and injected i.p. at a dose of 30 mg/kg of body 
weight in a volume of 200 μL. 5-Bromo-2’-deoxyuridine 
(Sigma, St. Louis, MO) was dissolved in water and injected 
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Proliferation 
  After two weeks of habituation, male ICR mice were 
injected with 30 mg/kg METH or saline vehicle (i.p). After 
METH, different groups of animals were injected with 100 
mg/kg of bromo-deoxyuridine at the following times: 2, 24, 
36 hours, 2, 3, 4, 5, 6, 7, 14 and 21 days. To allow for a 
complete round of mitotic cell division, animals were sacri-
ficed 24 hours after the bromo-deoxyuridine injection. They 
were anesthetized with a mixture of 100mg/kg ketamine + 3 
mg/kg acepromazine, then perfused with PBS, followed by 
4% paraformaldehyde in PBS. Following perfusion, the 
brains were removed from the skull and post-fixed in 4 % 
paraformaldehyde overnight at 4
oC, then cryo-protected in 
30% sucrose in PBS solution for 24 hours at 4
oC. After cryo-
protection, the brains were stored at 80
oC until used. 
Apoptosis of Newly Generated Cells 
  49 Male ICR mice received a single METH injection 
(30mg/kg, i.p.) followed by a single 100mg/kg injection of 
bromo-deoxyuridine at 1.5 days post-METH. In order to 
quantify the percentage of the new cells displaying pyknotic 
nuclei, seven animals were randomly sacrificed and the tis-
sue collected within five hours after the bromodeoxyuridine 
injection. Total bromodeoxyuridine incorporation into nuclei 
from these animals was used as baseline for comparison. The 
other animals were randomly sacrificed at the following 
post-METH time points: 2 days, 1, 2, 4, 8 or 12 weeks. Tis-
sue was collected and processed in the same manner as in the 
proliferation study above. 
Immunohistochemistry 
  Coronal sections from one hemisphere were cut at 40 μm 
thickness and serially collected from the striatum between 
bregma 0.02 and 1.4 mm [18]. Six sections per animal were 
processed using the free-floating method. Fluorescent immu-
nostaining was visualized and quantified as follows: PBS 
wash, followed by incubation at 65
oC in a solution of 1:1 
formamide and 0.375M sodium chloride/0.0375M sodium 
citrate (pH 7) for two hours, then incubation in 2N HCL at 
37
oC for 30 minutes. After a 10-minute rinse in 0.1M boric 
acid (pH 8.5), non-specific binding sites were blocked with 
5% donkey serum in 0.2% Triton X100 in PBS at room tem-
perature for one hour. Sections were then incubated in pri-
mary antibody, sheep anti-bromo-deoxyuridine immuno-
globulin (1:500; Novus Biologicals, Littleton, CO) in 1% 
donkey serum overnight at 4
oC. After two PBS washes (five 
minutes each), the sections were incubated for one hour in 
secondary antibody, donkey anti-sheep conjugated to FITC 
(1:500; Novus Biologicals, Littleton, CO) at room tempera-
ture. After two washes in PBS (five minutes each), the sec-
tions were mounted onto superfrost glass slides, sealed and 
coverslipped with Vectorshield hard set
TM mounting medium 
for fluorescence (Vector Laboratories, Burlingame CA). 
Quantification and Statistical Analysis 
  For the proliferation study, data from eight METH and 
five control animals from each time point were analyzed. For 
the apoptosis study, seven animals per survival time point 
were analyzed. Each tissue sample was counted by two dif-
ferent individuals blind to the treatment condition to ensure a 
minimum 95% correlation in criteria. Proliferating cells were 
defined as bromo-deoxyuridine-positive nuclei that morpho-
logically appeared to have divided. (see Fig. 1C). Apoptosis 
was defined as intensely stained bromo-deoxyuridine-
positive round or crescent shaped clumps of compact nuclei 
indicative of karyopyknosis. 
  Mean number of nuclei and striatal volumes were quanti-
fied using unbiased stereology powered by Stereologer
TM 
software/hardware system from Stereology Resource Center 
(Chester, MD), connected to a Leica DM 2500 microscope 
from Leica Microsystems Inc. (Wetzlar, Germany) and a 
MAC-pro computer system. A cross section of the striatum 
was outlined at 5X magnification for each tissue sample (see 
Fig. 1A). Stereologer’s dissector probe was used for count-
ing and calculating the mean number of nuclei meeting mi-
totic or pyknotic criteria that fell within the inclusion lines of 
the optical dissector at 100X magnification. Guard volume 
was taken as the first and last two micrometers of tissue in 
cross section. Cells within the guard volume were excluded 
from the analysis. Statistical analysis was done using Prism 
software (GraphPad inc. La Jolla, CA). For proliferation, a 
two-way ANOVA was done to compare mean bromo-
deoxyuridine-positive nuclei for each treatment condition at 
each time point. Post-hoc analysis included Bonferroni mul-
tiple comparisons test of significant differences. For pykno-
sis, the percent difference of bromo-deoxyuridine-positive 
nuclei at 1.5 days post-METH and bromo-deoxyuridine-
positive nuclei that were pyknotic at each time point was 
calculated and a one-way ANOVA with Dunnet’s multiple 
comparisons test of differences between 1.5 days post-
METH and each of the other time points. The same type of 
analysis was performed for striatal volume except that the 
percent difference for each post-METH time point was cal-
culated and compared to saline controls at 1.5 days. 
RESULTS 
  In previous studies we showed that METH (30 mg/kg, ip) 
induced the apoptosis of approximately 25% of striatal neu-
rons 24 hours after a single bolus injection [17, 19]. In order 
to investigate the possibility of production of new cells in the 
aftermath of the striatal cell loss induced by METH, we in-
jected mice (n=8 per group) with METH (30 mg/kg, i.p.) 
followed by an injection of bromo-deoxyuridine (100 mg/kg, 
i.p.) at various times after METH. Bromo-deoxyuridine is a 
DNA precursor that becomes incorporated into nascent DNA 
chains in place of thymidine during DNA replication prior to 
mitotic division. The cells labeled with bromo-deoxyuridine 
(new cells) can be reliably and conveniently visualized with 
immunohistochemical methods. Fig. (1) shows the emer-
gence of many new cells throughout the striatum at 36 hours 
after METH (Fig. (1B)). Control animals injected with saline 
display bromo-deoxyuridine-positive cells only in the sub-
ventricular zone (Fig. (1A)), an area of the adult brain that 
supports neurogenesis. The new cells shown in Fig. (1B) do 
not migrate to the striatum from the subventricular zone. We 
base this hypothesis on the observation that pairs of newly 
divided daughter cells can be found throughout all aspects of 
the striatum (Fig. (1C)). 
  In order to determine the time(s) after METH when new 
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deoxyuridine at various times after METH. In Fig. (2) is 
shown a time course of bromo-deoxyuridine-positive nuclei 
at various times after a bolus injection of METH. There is a 
narrow window between 24 and 48 hours after METH when 
new cells emerge throughout the striatum (Fig. (2)). The 
newly generated cells are not stable and begin to disappear at 
2.5 days after METH, or 24 hours after birth (Fig. (3)). The 
bulk of the newly generated cells die by a mechanism of 
apoptosis displaying pyknotic morphology in their nuclei 
(data not shown). The new cells continue to die for a period 
of 12 weeks at which time the majority of the cells (ap-
proximately 60%) have disappeared (Fig. (3)). At the time 
when the new cells appear and for most of the 12-week pe-
riod of protracted cell death the striatum displays an en-
largement due to an increase in volume as determined by 
automated unbiased stereology (Fig. (4)). The enlargement 
of the striatum is largest at one week post-METH because 
two animals displayed abnormally large striata relative to 
controls (Fig. (4)). The percent increases at 2.5 days and 2 and 4 
weeks after METH in Fig. (4) did not approach statistical 
significance at the 95% confidence level. Interestingly, the 
enlarged striatal morphology normalizes over time (Fig. (4)). 
DISCUSSION 
  The results presented in this study demonstrate that expo-
sure to a single high dose of METH induces the production 















Fig. (1). METH induces the generation of new cells in the striatum. Male mice (n=8) were given METH (30 mg/kg, i.p.) followed by bromo-
deoxyuridine (100 mg/kg, i.p.) 36 hours after METH. New cells were visualized by immunostaining with an antibody against bromo-
deoxyuridine. There was no bromo-deoxyuridine incorporation in the striatum of mice treated with saline (A), however, several bromo-
deoxyuridine-positive cells (B) are visible throughout all aspects of the striatum. Note at high magnification (100x) the presence of daughter 
cells that appear to have completed mitotic division (C). Bromo-deoxyuridine incorporation is visible in the subventricular zone (SVZ) be-









Fig. (2). Time course of incorporation of bromo-deoxyuridine into 
new cells of the striatum after treatment with METH (0 time point). 
Mice (n=8) were injected with METH (30 mg/kg, i.p.) and were 
given an injection of bromo-deoxyuridine (100 mg/kg, i.p.) at the 
times indicated under the x-axis. Sections of striatal tissue were 
processed for immunohistochemistry with an antibody against 
bromo-deoxyuridine. Cells were counted throughout the striatum by 
automated unbiased stereology. Note the 24-hour window between 
24 and 48 hours in which robust proliferation of cells occurs in the 
striatum after METH treatment. Data were analyzed by two-way 
ANOVA for comparison between the mean number of nuclei with 
bromo-deoxyuridine incorporation per condition per time point. 
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hours after METH. The emergence of new cells is associated 
with enlarged striatal volume. The newly generated cells are 
unstable and begin to die from one day after birth up to three 
months, a phase we refer to as protracted cell death. Most of 
the newly generated cells die by an apoptotic mechanism 
associated with pyknotic morphology of the nuclei. The pro-
tracted cell death induced by METH is different from the 
initial phase of cell loss occurring within the first 24 hours 
after METH. This initial phase involves the loss of approxi-
mately 25% of striatal neurons: projection neurons and par-
valbumin and cholinergic interneurons. The somatostatin/ 
NPY/NOS interneurons are resistant to METH [19]. Other 
laboratories have also reported the METH-induced loss of 
some striatal neurons using TUNEL [15] or Fluoro-Jade C 
[20]. The protracted phase of striatal cell death induced by 
METH is restricted to the newly generated cells most of 
which express the phenotype of glial cells (data not shown). 
Work in progress in this laboratory is characterizing the phe-
notype and survival of the newly generated cells in the af-
termath of METH. 
  Our results demonstrate that the production of new cells 
is associated with enlarged striatal morphology. This obser-
vation is particularly significant in the light of recent studies 
showing enlarged striatal volumes in METH users [9, 10, 
21]. One study reported that subjects with enlarged putamen 
and globus pallidus had relatively normal cognitive perform-
ance compared to subjects with smaller striatal structures 
suggesting a compensatory response [9]. Our data demon-
strate that the enlarged striatal volume normalizes over a 
period of three months in mice, the same amount of time 
associated with the bulk of the protracted cell death (see 
Figs. 3 & 4). The human study that found enlarged striatal 
volumes [9] involved METH users. However, a study assess-
ing abstinent METH users drug-free for approximately two 
years reported normal striatal volumes [22]. Our results show 
that the mouse striatum normalizes over a period of three 
months as most of the newly generated cells die by apopto-
sis, suggesting that the enlarged striatal volumes observed in 
METH users may be accounted for by inflammation and the 
production of new cells. 
  In conclusion, a bolus high dose of METH induces the 
genesis of cells in the striatum immediately following the 
loss of striatal neurons. The production of new cells is asso-
ciated with enlarged striatal volume that normalizes over a 
period of three months as the new cells die by apoptosis. A 
similar pattern of striatal enlargement has been reported with 
human METH use and normalization after protracted absti-
nence. More work is needed to determine the role played by 
the new cells in the aftermath of METH in the striatum. 
ACKNOWLEDGEMENTS 
  Special thanks are given to Ms. Ina Mexhitaj, Ms. Nane 
Ghazaryan and Mr. Alexander Davidis for technical assis-
tance. This work was supported by R01 DA020142 from   
the National Institute on Drug Abuse to JAA. Support for 
infrastructure came from the Research Centers in Minority 
Institutions grant awarded to Hunter College by NCRR/NIH. 
REFERENCES 
[1]   United Nations Office on Drugs and Crime (UNODC). World Drug 
Report  2007. Vienna, Austria: UNODC Research and Analysis 
Section,  2007. Reference Available from: http://www.unodc.org/ 
pdf/research/wdr07/WDR_2007.pdf [Accessed on: 27th September, 
2008]. 
[2]   Ellinwood, E.H., Jr. Assault and homicide associated with   
amphetamine abuse. Am. J. Psychiatry, 1971, 127, 1170-1175. 
[3]   Szuster, R.R. Methamphetamine in psychiatric emergencies.   
Hawaii Med. J., 1990, 49, 389-391. 
[4]   McCann, U.D., Wong, D.E., Yokoi, E., Villemagne, V., Dannals, 
R.E., Ricaurte, G.A. Reduced striatal dopamine transporter density 
in abstinent methamphetamine and methcathinone users: evidence 
from positron emission tomography. J. Neurosci., 1998, 18, 8417-
8422. 
[5]   Sekine, Y., Iyo, M., Ouchi, Y., Matsunaga, T., Tsukada, H., Okada, 
H., Yoshikawa, E., Futatsubashi, B.A., Takei, N., Mori, N.   








Fig. (3). The majority of the newly generated cells die over a three-
month period by apoptosis. Mice were treated as in Fig. (2) above 
and the number of pyknotic nuclei (apoptosis) were counted at 
various times using unbiased stereology starting at 2.5 days after 
METH. Pyknotic nuclei with bromo-deoxyuridine immunostaining 
were counted throughout the striatum. Note that the some newly 
generated cells display the pyknotic phenotype 24 hours after birth, 
or 2.5 days after METH (bromo-deoxyuridine was injected 1.5 days 
post-METH). One-way ANOVA showed significant differences 
between the percent of bromo-deoxyuridine-positive nuclei with 
pyknotic morphology at various time points after METH in com-









Fig. (4). METH induces an increase in striatal volume that normal-
izes over time. Striatal volume was determined using automated 
unbiased stereology at the times indicated under the x-axis after a 
bolus injection of METH (30 mg/kg, i.p.). Note that striatal vol-
umes decrease to near control levels at 8 and 12 weeks post-METH. 
*p<0.05. Methamphetamine Induces Striatal Cell Death Followed by the Generation  Current Neuropharmacology, 2011, Vol. 9, No. 1    83 
dopamine transporters studied with PET. Am. J. Psychiatry, 2001, 
158, 1206-1214. 
[6]   Sekine, Y., Ouchi, Y., Takei, N., Yoshikawa, E., Nakamura, K., 
Futatsubashi, M., Okada, H., Minabe, Y., Suzuki, K., Iwata, Y., 
Tsuchiya, K.J., Tsukada, H., Iyo, M., Mori, N. Brain serotonin 
transporter density and aggression in abstinent methamphetamine 
abusers. Arc. Gen. Psychiatry, 2006, 63, 90-100.  
[7]   Volkow, N., Chang, L., Wang, G., Fowler, J., Leonido-Yee, M., 
Franceschi, D., Sedler, M.J., Gatley, S. J., Hitzemann, R., Ding, Y.-S. 
Association of dopamine transporter reduction with psychomotor 
impairment in methamphetamine abusers. Am. J. Psychiatry, 2001, 
158, 377-382. 
[8]   Thompson, P.M., Hayashi, K.M., Simon, S.L., Geaga, J.A., Hong, 
M.S., Sui, Y., Lee, J.Y., Toga, A.W., Ling, W., London, E.D. 
Structural abnormalities in the brains of human subjects who use 
methamphetamine. J. Neurosci., 2004, 24, 6028-6036. 
[9]   Chang, L., Cloak, C., Patterson, K., Grob, C., Miller, E.N., Ernst, 
T. Enlarged striatum in abstinent methamphetamine abusers: a pos-
sible compensatory response. Biol. Psychiatry, 2005, 57, 967-974. 
[10]   Jernigan, T.L., Gamst, A.C., Archibald, S.L., Fennema-Notestine, 
C., Mindt, M.R., Marcotte, T.L., Heaton, R.K., Ellis, R. J., Grant, I. 
Effects of methamphetamine dependence and HIV infection on 
cerebral morphology. Am. J. Psychiatry, 2005, 162, 1461-1472. 
[11]   Seiden, L.S., MacPhail, R.C., Oglesby, M.W. Catecholamines and 
drug-behavior interactions. Fed. Proc., 1975, 34, 1823-1831. 
[12]   Woolverton, W.L., Ricaurte, G.A., Forno, L.S., Seiden, L.S. Long-
term effects of chronic methamphetamine administration in rhesus 
monkeys. Brain Res., 1989, 486, 73-78. 
[13]   Hanson, G.R., Gibb, J.W., Metzger, R.R., Kokoshka, J.M.,   
Fleckenstein, A.E. Methamphetamine-induced rapid and reversible  
reduction in the activities of tryptophan hydroxylase and dopamine 
transporters: oxidative consequences. Ann. N.Y. Acad. Sci., 1998, 
844, 103-107. 
[14]   Ricaurte, G.A., Guillery, R.W., Seiden, L.S., Schuster, C.R., 
Moore, R.Y. Dopamine nerve terminal degeneration produced by 
high doses of methylamphetamine in the rat brain. Brain Res., 
1982, 235, 93-103. 
[15]   Deng, X., Wang, Y., Chou, J., Cadet, J.L. Methamphetamine 
causes widespread apoptosis in the mouse brain: evidence from us-
ing an improved TUNEL histochemical method. Brain Res. Mol. 
Brain Res., 2001, 93, 64-69. 
[16]   Eisch, A.J., Marshall, J.F. Methamphetamine neurotoxicity: disso-
ciation of striatal dopamine terminal damage from parietal cortical 
cell body injury. Synapse, 1998, 30, 433-445. 
[17]   Zhu, J.P.Q., Xu, W., Angulo, J.A. Disparity in the temporal   
appearance of methamphetamine-induced apoptosis and depletion 
of dopamine terminal markers in the striatum of mice. Brain Res., 
2005, 1049, 171-181. 
[18]   Franklin, K.B.J., Paxinos, G. The Mouse Brain in Stereotaxic   
Coordinates. The Academic Press: New York, 1997. 
[19]   Zhu, J.P.Q., Xu, W., Angulo, J.A. Methamphetamine-induced cell 
death: Selective vulnerability in neuronal subpopulations of the 
striatum in mice. Neuroscience, 2006, 140, 607-622. 
[20]   Bowyer, J.F., Robinson, B., Ali, S.F., Schmued, L.C. Neurotoxic-
related changes in tyrosine hydroxylase, microglia, myelin, and 
blood-brain barrier in the caudate-putamen from acute metham-
phetamine exposure. Synapse, 2008, 62, 193-204. 
[21]   Chang, L., Alicata, D., Ernst, T., Volkow, N. Structural and meta-
bolic brain changes in the striatum associated with methampheta-
mine abuse. Addiction, 2007, 102, 16-32. 
[22]   Oh, J.S., Lyoo, I.K., Sung, Y.H., Hwang, J., Kim, J., Chung, A., 
Park, K.S., Kim, S.J., Renshaw, P.F., Song, I.C. Shape changes of 
the corpus callosum in abstinent methamphetamine users. Neurosci. 
Lett., 2005, 384, 76-81. 
 
 
Received: October 01, 2009  Revised: April 17, 2010  Accepted: May 26, 2010 
 
 